WO2017074895A1 - Nouvelles formulations - Google Patents

Nouvelles formulations Download PDF

Info

Publication number
WO2017074895A1
WO2017074895A1 PCT/US2016/058583 US2016058583W WO2017074895A1 WO 2017074895 A1 WO2017074895 A1 WO 2017074895A1 US 2016058583 W US2016058583 W US 2016058583W WO 2017074895 A1 WO2017074895 A1 WO 2017074895A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
weight
composition according
glycerin
oil
Prior art date
Application number
PCT/US2016/058583
Other languages
English (en)
Inventor
Martyn J. CLARKE
Swati J. MODI
Pallav Arvind Bulsara
Dara L. Dinner
Original Assignee
Glaxosmithkline Consumer Healthcare Holdings (Us) Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Consumer Healthcare Holdings (Us) Llc filed Critical Glaxosmithkline Consumer Healthcare Holdings (Us) Llc
Publication of WO2017074895A1 publication Critical patent/WO2017074895A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips

Definitions

  • the present invention relates to a novel moisturizing and barrier repair lip protectant composition comprising high levels of glycerin.
  • Unprotected skin is susceptible to dehydration and becoming irritated from exposure to the elements. This is especially true for the lips, which have been found to be even more vulnerable to water loss than typical skin. In this regard, the lips have a thinner stratum comeum and also contain lesser amounts of lipids than skin on other parts of the body. When the lipid barrier is depleted or is inadequate, the lips dry out becoming irritated and prone to cracking. Lips also contain less melanin than other areas of skin, and thus are at risk of sunburn and UV damage. Accordingly, effective lip protectant compositions are highly desirable.
  • a conventional lipstick includes five basic components: waxes, emollients, functional ingredients, stabilizers and colorants. Waxes and emollients tend to make up the base to which the other non-aqueous ingredients are added.
  • a lipstick base tends to be anhydrous and simply minimizes the amount of trans-epidermal water loss, rather than replace any lost moisture.
  • Moisturizing compositions are typically oil-in-water emulsions and usually contain thickeners and/or conventional emulsifiers to stabilize the emulsion. Such compositions have a relatively high water content and so are able to replace moisture lost from the stratum corneum. They also typically contain one or more humectants to help retain moisture. However, while moisturizing compositions temporarily decrease visible scaling and roughness of the skin, they may offer little improvement to the integrity of the stratum comeum barrier. In fact, common moisturizing compositions which contain conventional emulsifiers can actually cause disruptions to the barrier function of the skin. Thus, a composition with a high water content may suggest that the product provides good moisturization, but it will not necessarily maintain, protect or restore the barrier function of the skin.
  • U. S. Patent No. 5,643,899 discloses compositions directed specifically to the treatment of epidermal barrier disorders such as hyperproliferative cutaneous diseases, papulosquamous diseases, and eczematous diseases.
  • the disclosed compositions contain various combinations of essential lipids that include cholesterol and a ceramide, particularly acylceramide.
  • the compositions while described for repair of the epidermal barrier function do not discuss application to the lips.
  • U. S. Patent No. 5,508,034, Bernstein et al discloses compositions containing various lipids naturally found in the stratum comeum as essential components for the treatment of dry skin disorders. These compositions must contain a fatty acid, cholesterol, and a phospholipid or a glycolipid. The compositions while described for repair of the epidermal barrier function do not discuss application to the lips.
  • U. S. Patent No. 6,663,853, Singh discloses compositions as lip care moisturizing products which comprise fatty acid esters, a wax, an emulsifier and 1.0% unilamellar liposomes in a water-in-oil emulsion. The liposomes contain a mixture of water and glycerin.
  • WO 2012/104604 describes a blend for use in personal care compositions, which comprises at least one dialkyl amphiphilic component and at least one ester of a branched fatty acid and branched fatty alcohol.
  • the blend may be used as the oil phase of an oil-in- water emulsion composition.
  • the blend may further comprise a fatty acid and a fatty alcohol.
  • Blends prepared in accordance with WO 2012/104604 are commercially available from Croda International PLC as DuraQuenchTM blends.
  • DuraQuenchTM IQ comprises potassium cetyl phosphate, isostearyl isostearate, behenic acid, cetyl alcohol and cetyl behenate.
  • DuraQuenchTM IQ SA comprises potassium cetyl phosphate, isostearyl isostearate, stearic acid, cetyl alcohol and cetyl stearate.
  • the DuraQuenchTM blends are adapted for use in personal care compositions and provide moisturization to the skin by forming a layer on the skin's surface and regulating water loss. See also Pennick et al, Intl J Cos Sci, 34, P 567-574 (2012).
  • an object of the present invention is to provide a topical composition that is effective in moisturizing and minimizing trans-epidermal water loss, while also protecting and repairing the barrier function of the lips.
  • a further object of the present invention is to provide a topical composition which is convenient, easily applied to the lips and cosmetically elegant.
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount greater than about 12% by weight, based on the total weight of the composition;
  • composition is a lip protectant composition.
  • the glycerin in the aqueous phase is present in an amount from about 12% to about 40% by weight, based on the total weight of the composition. In another embodiment, the glycerin in the aqueous phase is present in an amount from about 20% to about 30% by weight, based on the total weight of the composition. In yet another embodiment, the glycerin in the aqueous phase is present in an amount from about 20% to about 25% by weight, based on the total weight of the composition.
  • Another embodiment of the disclosure is a method for moisturizing, and protecting, repairing, or restoring the skin lipid barrier of the lips of a mammal, the method comprising applying to the lips of the mammal in need thereof a therapeutically effective amount of a topical oil-in-water emulsion composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount greater than about 12% by weight, based on the total weight of the composition;
  • composition is a lip protectant composition.
  • the glycerin in the aqueous phase is present in an amount from about 12% to about 40% by weight, based on the total weight of the composition. In another embodiment, the glycerin in the aqueous phase is present in an amount from about 20% to about 30% by weight, based on the total weight of the composition. In yet another embodiment, the glycerin in the aqueous phase is present in an amount from about 20% to about 25% by weight, based on the total weight of the composition.
  • Another embodiment of the disclosure is a method of protecting the lips of a mammal with broad spectrum protection of a UVA and UVB sunscreen, and enriched in UVA protection, the method comprising applying to the lips of the mammal in need thereof an effective amount of a topical oil-in-water emulsion composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount greater than about 12% by weight, based on the total weight of the composition;
  • UVA SPF protection is about 1 : 1 ;
  • composition is a lip protectant composition.
  • the glycerin in the aqueous phase is present in an amount from about 12% to about 40% by weight, based on the total weight of the composition. In another embodiment, the glycerin in the aqueous phase is present in an amount from about 20% to about 30% by weight, based on the total weight of the composition. In yet another embodiment, the glycerin in the aqueous phase is present in an amount from about 20% to about 25% by weight, based on the total weight of the composition.
  • the 1 : 1 protection ratio helps to protect against UVA induced photodegradation of pheomelanin.
  • the UVA sunscreen is
  • the UVB sunscreen is Ethylhexyl Salicylate
  • composition further comprises a similiter stabilizer.
  • sunfilter stabilizer is Diethylhexyl Syringylidene Malonate.
  • Another embodiment of the disclosure is a method of protecting the lips of a mammal against reactivation of herpes simplex virus, the method comprising applying to the lips of the mammal in need thereof an effective amount of a topical oil-in-water emulsion composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount greater than about 12% by weight, based on the total weight of the composition;
  • At least one lamellar membrane structure comprising (i) a dialkyl amphiphilic component and (ii) an ester of a branched fatty acid and a branched fatty alcohol;
  • composition is a lip protectant composition.
  • Yet another embodiment of the disclosure is a method of protecting the lips of a mammal against a reoccurrence of cold sores, the method comprising applying to the lips of the mammal in need thereof an effective amount of a topical oil-in-water emulsion composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount greater than about 12% by weight, based on the total weight of the composition;
  • At least one lamellar membrane structure comprising (i) a dialkyl amphiphilic component and (ii) an ester of a branched fatty acid and a branched fatty alcohol;
  • composition is a lip protectant composition.
  • Figure 1 illustrates key physical differences between an oil in water emulsion that can form a lamellar structure (A) and a liposome (B).
  • the invention provides a topical oil-in-water emulsion composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount greater than about 12% by weight, based on the total weight of the composition;
  • composition is a lip protectant composition.
  • the glycerin in the aqueous phase is present in an amount from about 12% to about 40% by weight, based on the total weight of the composition. In another embodiment, the glycerin in the aqueous phase is present in an amount from about 20% to about 30% by weight, based on the total weight of the composition. In yet another embodiment, the glycerin in the aqueous phase is present in an amount from about 20% to about 25% by weight, based on the total weight of the composition.
  • the composition is a lipstick. In another embodiment, the composition is a lip balm. In yet another embodiment, the composition is a stick lip balm. In a further embodiment, the composition is a lip cream. Oil phase
  • compositions of this disclosure comprise a discontinuous oil phase.
  • the discontinuous oil phase is dispersed throughout the continuous aqueous phase.
  • the discontinuous oil phase comprises at least one oil and/or fat.
  • the oil and/or fat is a mixture of two or more oils and/or fats.
  • oils and fats include, but are not limited to, fatty acids, a source of fatty acids, fatty alcohols, esters, esters of glycerin (including mono-, di- and tri-esters), waxes, sterols, hydrocarbons, essential oils, vegetable oils and edible oils, and mixtures thereof.
  • Exemplary fatty acids include, but are not limited to, isostearic acid, linoleic acid, linolenic acid, oleic acid, myristic acid, ricinoleic acid, columbinic acid, arachidic acid, arachidonic acid, lignoceric acid, nervonic acid, eicosapentanoic acid, palmitic acid, stearic acid and behenic acid, and mixtures thereof.
  • the fatty acid can be introduced into the present compositions from a variety of sources.
  • the fatty acid is provided in the composition as an oil or wax.
  • oils or waxes useful in this regard include, but are not limited to, rice bran oil or rice bran wax, flaxseed oil, hempseed oil, pumpkin seed oil, canola oil, soybean oil, wheat germ oil, olive oil, grapeseed oil, borage oil, evening primrose oil, black currant seed oil, chestnut oil, corn oil, safflower oil, sunflower oil, sunflower seed oil, cottonseed oil, peanut oil, sesame oil and olus (vegetable) oil, including hydrogenated versions, and mixtures thereof.
  • Rice bran oil is also known as Oryza Sativa bran oil, and rice bran wax is also known as Oryza Sativa Cera.
  • Rice bran oil has a composition similar to peanut oil, with 38% monounsaturated, 37% polyunsaturated and 25% saturated fatty acids.
  • Rice bran wax is the vegetable wax extracted from the bran oil of rice. It contains C16-C30 fatty acids.
  • the source of fatty acids is shea butter, also known as Butyrospermum parkii.
  • Shea butter which has been chemically treated, comprises five principal fatty acids, namely palmitic acid, stearic acid, oleic acid, linoleic acid and arachidic acid. Shea butter also comprises phytosterols.
  • oil or wax is suitably selected from flaxseed oil, hempseed oil, pumpkin seed oil, canola oil, soybean oil, wheat germ oil, olive oil, grapeseed oil, borage oil, evening primrose oil, black currant seed oil, chestnut oil, com oil, safflower oil, sunflower oil, sunflower seed oil, cottonseed oil, peanut oil, sesame oil and olus
  • the source of fatty acids is olus (vegetable) oil, olive oil or rice bran oil.
  • the source of fatty acids is rice bran oil, or a mixture of rice bran oil and rice bran wax.
  • Exemplary fatty alcohols include, but are not limited to, behenyl alcohol, isostearyl alcohol, caprylyl alcohol, decyl alcohol, lauryl alcohol, myristyl alcohol, lanolin alcohol, arachidyl alcohol, oleyl alcohol, palm alcohol, isocetyl alcohol, cetyl alcohol, stearyl alcohol and cetearyl alcohol, and mixtures thereof.
  • the fatty alcohol is behenyl alcohol.
  • esters include, but are not limited to, coco-caprylate/caprate, diethyl sebacate, diisopropyl adipate, diisopropyl dilinoleate, ethyl oleate, ethylhexyl hydroxystearate, glycol distearate, glycol stearate, hydroxy octacosanyl hydroxystearate, isopropyl isostearate, isostearyl isostearate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, methyl glucose sesquistearate, methyl laurate, methyl salicylate, methyl stearate, myristyl lactate, octyl salicylate, oleyl oleate, PPG-20 methyl glucose ether distearate, propylene glycol diacetate, propylene glycol dicaprylate, propylene glycol monolaurate,
  • esters of glycerin include, but are not limited to, caprylic/capric triglycerides, caprylic/capric/succinic triglyceride, cocoglycerides, glyceryl citrate, glyceryl isostearate, glyceryl laurate, glyceryl monostearate, glyceryl oleate, glyceryl palmitate, glyceryl ricinoleate, glyceryl stearate, mono and diglyceride, PEG-12 glyceryl laurate, PEG-120 glyceryl stearate, polyglyceryl-3 oleate, polyoxyl glyceryl stearate, tallow glycerides and medium chain triglycerides, and mixtures thereof.
  • the ester of glycerin is a mono-, di- or triglyceride, such as caprylic/capric triglyceride.
  • the triglycerides are isolated from palm oil.
  • Waxes typically serve as a structurant for stick lip balms permitting the stick to be extended and retracted in use while maintaining the stick form.
  • Suitable waxes for stick compositions and other embodiments of the invention include animal waxes, plant waxes, mineral waxes, silicone waxes, synthetic waxes and petroleum waxes.
  • Exemplary waxes include, but are not limited to, rice bran wax, camauba wax, paraffin wax, white wax, candelilla wax, beeswax, jojoba wax, ozokerite and a ceramide, and mixtures thereof.
  • the wax is a wax is a spingolipid or a spingolipid mimic.
  • Ceramides are a family of waxy lipid molecules composed of sphingosine and a fatty acid. They contain an acyl linkage and the chain length of the most abundant chain is C24-C26 with a small fraction having an acyl chain length of C16-C 18. Ceramides are found extensively in the stratum comeum. Ceramides are commercially available from major chemical suppliers such as Evonik or Sigma Chemical Company, St. Louis, Mo., U. S.A.
  • Exemplary ceramides useful in the present compositions include, but are not limited to, ceramide-1 , -2, -3, -4, -5, -6 or -7, and mixtures thereof.
  • Other ceramides known to those of skill in the art as useful in topical compositions are further contemplated as useful in the present compositions, such as those described in The Merck Index, Thirteenth Edition, Budavari et al, Eds., Merck & Co., Inc., Rahway, N.J. (2001); the CTFA (Cosmetic, Toiletry, and Fragrance Association) International Cosmetic Ingredient Dictionary and Handbook, Tenth Edition (2004); and the "Inactive Ingredient Guide", U. S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of
  • the ceramide is ceramide-3.
  • Ceramides, acylceramides and glucosylceramides are all members of the "sphingoid" or "spingolipids” class. As noted above, these are compounds which have a backbone of sphingosine or a closely related structure to which either fatty acids or ⁇ -esterified fatty acids are linked through an amide linkage at the amino group of the sphingosine structure and in the case of a glucosylceramide, those to which saccharide moieties are linked to the terminal hydroxyl of the sphingosine structure through a glycosidic bond.
  • Exemplary sterols include, but are not limited to, Brassica Campestris sterols, C10-C30 cholesterol / lanosterol esters, canola sterols, cholesterol, cholesterols, glycine soja sterols, PEG-20 phytosterol and phytosterols, and mixtures thereof.
  • phytosterol refers to plant sterols and plant stanols. Plant sterols are naturally occurring cholesterol-like molecules found in all plants, with the highest concentrations occurring in vegetable oils. Plant stanols are hydrogenation compounds of the respective plant sterols.
  • Phytosterols are natural components of common vegetable oils.
  • exemplary sources of phytosterols useful in this regard include, but are not limited to, shea butter, vegetable oil, tall oil, sesame oil, sunflower oil, sunflower seed oil, rice bran oil, cranberry seed oil, pumpkin seed oil and avocado wax, and mixtures thereof.
  • the source of phytosterols is shea butter.
  • compositions contain cholesterol, or an animal- based sterol, rather than a phytosterol.
  • a phytosterol in embodiments of the present invention, rather than cholesterol, is advantageous.
  • phytosterols are typically incorporated in the basal membrane of the skin and can pass to the skin surface through the differentiation of skin cells. Accordingly, phytosterols provide an improved caring and protecting effect.
  • the topical application of phytosterols also usually leads to an increased skin moisture level and to increased lipid content. This improves the desquamation behavior of the skin and reduces erythemas which may be present.
  • R. Wachter, Parf. Kosm, Vol. 75, p. 755 (1994) and R. Wachter, Cosm. Toil, Vol. 1 10, p. 72 (1995), each of which are incorporated herein by reference in their entirety, further demonstrate these advantageous properties of phytosterols.
  • cholesterol derivative is any suitable dermatologically acceptable sterol variation of cholesterol.
  • hydrocarbons include, but are not limited to, dodecane, petrolatum, mineral oil, squalane, squalene and paraffin, and mixtures thereof.
  • the hydrocarbon is squalane.
  • Squalane helps enhance the skin's natural barrier function, protect the skin against the elements, and boost the skin's ability to retain moisture.
  • Squalane is a component of human stratum corneum.
  • Squalane is available in purified form (see e.g. Fitoderm® available from BASF) and may be used in the compositions in its purified form. Alternatively, an oil which is rich in squalane may be used.
  • Exemplary sources of squalane useful in the present compositions include, but are not limited to, shark liver oil, olive oil, palm oil, wheat germ oil, amaranth oil, rice bran oil and sugar cane.
  • the squalane is isolated from olive oil.
  • Exemplary essential oils include, but are not limited to, primrose oil, rose oil, eucalyptus oil, borage oil, bergamot oil, chamomile oil, citronella oil, lavender oil, peppermint oil, pine oil, pine needle oil, spearmint oil, tea tree oil and wintergreen oil, and mixtures thereof.
  • Exemplary vegetable oils include, but are not limited to, olus (vegetable) oil, almond oil, aniseed oil, canola oil, castor oil, coconut oil, com oil, avocado oil, cottonseed oil, olive oil, palm kernel oil, peanut oil, sunflower oil, safflower oil and soybean oil, and mixtures thereof.
  • One embodiment is the use of olive oil and/or vegetable oil.
  • Exemplary edible oils include, but are not limited to, cinnamon oil, clove oil, lemon oil and peppermint oil, and mixtures thereof.
  • the oil and/or fat is a fatty acid, a source of fatty acids, or an ester of glycerin as described herein.
  • many of the oils and/or fats used in the present compositions are the same or similar to the lipids found in human stratum comeum.
  • the discontinuous oil phase is present in an amount from about 20% to about 70% by weight, based on the total weight of the composition.
  • compositions of the invention comprise a continuous aqueous phase.
  • the aqueous phase comprises water.
  • any additional components such as glycerin and any other water soluble excipients will be dissolved in this aqueous phase.
  • the continuous aqueous phase is present in an amount from about 10% to about 90% by weight, based on the total weight of the composition.
  • the continuous aqueous phase is present in an amount from about 25% to about 75% by weight, based on the total weight of the composition.
  • the continuous aqueous phase is present in an amount from about 10% to about 70% by weight, based on the total weight of the composition.
  • the continuous aqueous phase comprises water in an amount from about 10 to about 60% by weight, in another embodiment from about 20% to about 40% by weight, and in another embodiment from about 10% to about 35% by weight, based on the total weight of the composition.
  • the continuous aqueous phase comprises glycerin present in an amount from about 12% to about 40% by weight, based on the total weight of the composition. In another embodiment, the continuous aqueous phase comprises glycerin in an amount from about 18% to about 30% by weight, based on the total weight of the composition. In another embodiment, the continuous aqueous phase comprises glycerin in an amount from about 20% to about 40% by weight, based on the total weight of the composition. In another embodiment, the continuous aqueous phase comprises glycerin in an amount from about 20% to about 30% by weight, based on the total weight of the composition.
  • the continuous aqueous phase comprises glycerin in an amount from about 20% to about 25% by weight, based on the total weight of the composition. In another embodiment, the continuous aqueous phase comprises glycerin in an amount of about 20%, 21 %, 22%, 23%, 24 or 25% by weight, based on the total weight of the composition.
  • the continuous aqueous phase may also include a sugar alcohol, such as glucose, glycerol, sorbitol, mannitol, maltitol, galactitol, erythritol, xylitol, inositol, lactitol, and mixtures thereof.
  • the sugar alcohol is glucose.
  • the sugar alcohol may be present in an amount from about 1% to about 20% by weight, based on the total weight of the composition. In one embodiment of the disclosure, the amount of sugar alcohol is from about 10% to about 15% by weight, based on the total weight of the composition. In an embodiment, the amount of sugar alcohol is about 10, 1 1, 12, 13, 14 or 15% by weight, based on the total weight of the composition.
  • the continuous aqueous phase may further comprise other water miscible components, such as for example, humectants and pH adjusting agents.
  • compositions of the invention comprise a thickening agent or rheology modifier.
  • the thickening agent is a mixture of two or more thickening agents.
  • the function of the thickening agent is to stabilize the discontinuous oil phase of the composition.
  • the thickening agent may also provide hardness and structural support useful in forming a stick composition, for example.
  • Thickening agents may be water miscible which are used to thicken the aqueous portion of the emulsion composition.
  • thickening agents are nonaqueous making them suitable for thickening the oil phase of the emulsion composition. Yet other thickening agents may act at the oil-water interface and thus lie at the interphase boundary.
  • Exemplary water miscible thickening agents include, but are not limited to, a cellulose derivative such as carboxymethylcellulose, hydroxy ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose; agar; carrageenan; curdlan; gelatin; gellan; ⁇ -glucan; tragacanth gum; guar gum; gum arabic; locust bean gum; pectin; starch; a carbomer, such as sodium carbomer; a xanthan derivative such as dehydroxanthan gum and xanthan gum; salts thereof, or a combination or mixture thereof.
  • a cellulose derivative such as carboxymethylcellulose, hydroxy ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose
  • agar carrageenan
  • curdlan gelatin
  • ⁇ -glucan tragacanth gum
  • guar gum gum arabic
  • locust bean gum locust bean gum
  • pectin starch
  • nonaqueous thickening agents include, but are not limited to, acrylate copolymers, VP/Eicosene copolymer, waxes, fatty alcohols and fatty acids such as described herein.
  • the thickening agent is an aery late copolymer, such as acrylates/C 10-30 alkyl acrylate cross polymer.
  • the thickening agent is xanthan gum. In another embodiment, the thickening agent is dehydroxanthan gum. In yet another embodiment, the thickening agent is a carbomer or a salt thereof, such as sodium carbomer. In a further embodiment, the thickening agent is hydroxy ethylcellulose.
  • the thickening agent is a fatty alcohol.
  • Suitable fatty alcohols include, but are not limited to, behenyl alcohol, isostearyl alcohol, caprylyl alcohol, decyl alcohol, lauryl alcohol, myristyl alcohol, lanolin alcohol, arachidyl alcohol, oleyl alcohol, palm alcohol, isocetyl alcohol, cetyl alcohol, stearyl alcohol and cetearyl alcohol, and mixtures thereof.
  • the thickening agent comprises a mixture of fatty alcohols, a cellulose derivative, a xanthan derivative, a non-aqueous agent, and a carbomer.
  • the thickening agent comprises behenyl alcohol, dehydroxanthan gum, VP/Eicosene copolymer, acrylates/C 10-30 alkyl acrylate cross polymer and sodium carbomer.
  • the thickening agent is present in an amount from about 0.5% to about 10% by weight, based on the total weight of the composition. In an embodiment, the thickening agent is present in an amount from about 1% to about 5% by weight, based on the total weight of the composition.
  • compositions of the invention comprise at least one lamellar membrane structure.
  • this refers to a planar lipid bilayer sheet, or a slight curve around a droplet of oil. They may also exist as separate discrete lamellae in the bulk aqueous phase. This is in contrast to a rounded formed liposomal structure.
  • the respective lamellar membrane structures form two or more stacked lamellar membrane structures. Two lamellar membrane structures stacked together, one on top of the other, is known as a double lamellar membrane structure.
  • Figure 1 illustrates the key physical difference between an oil in water emulsion that can form a lamellar structure (A) and a liposome (B).
  • the surfactant- emulsifiers orientate so that the hydrophilic heads face out into the continuous phase and the hydrophobic tails are anchored within the oil droplet.
  • these are typically aqueous filled cores where the hydrophilic heads of the interfacial layer of surfactant- emulsifer (here shown as a dialkyl phospholipid which can form liposomal structures) orientated toward the hydrophilic aqueous core and for the outermost layer, orientated towards the continuous phase.
  • the at least one lamellar membrane structure comprises (i) a dialkyl amphiphilic component and (ii) an ester of a branched fatty acid and a branched fatty alcohol. That is, the lamellar membrane structure comprises a blend of (i) a dialkyl amphiphilic component and (ii) an ester of a branched fatty acid and a branched fatty alcohol. This blend is referred herein as the lamellar membrane blend.
  • the lamellar membrane blend is present in an amount from about 5% to about 20% by weight, based on the total weight of the composition. In an embodiment, the lamellar membrane blend is present in an amount from about 5% to about 15% by weight, based on the total weight of the composition. In another embodiment, the lamellar membrane blend is present in an amount of about 8%, 9%, 10%, 11 % or 12% % by weight, based on the total weight of the composition. In another embodiment, the lamellar membrane blend is present in an amount of about 10% by weight, based on the total weight of the composition.
  • the lamellar membrane blend is solubilized in the oil phase of the oil- in-water emulsion.
  • long chain refers to a hydrocarbon backbone chain suitably composed of 12 to 36 carbon atoms.
  • the chain is 12 to 30 carbon atoms.
  • the chain is 16 to 26 carbon atoms.
  • the chain is 16 to 22 carbon atoms.
  • the chain is 22 to 30 carbon atoms.
  • the chain is 16 to 26 carbon atoms.
  • the chain is 16 to 22 carbon atoms.
  • the chain is 20 to 22 carbon atoms.
  • the chain is from 20 to 30 carbon atoms, suitably 22 to 30 carbon atoms.
  • the chain is from 22 to 28 carbon atoms.
  • fatty as used herein with reference to "fatty alcohol” or “fatty acid”, etc. refers to a "long chain" hydrocarbon backbone chain suitably composed of 12 to 30 carbon atoms.
  • the chain is 16 to 26 carbon atoms.
  • the chain is 16 to 22 carbon atoms.
  • the chain is 20 to 22 carbon atoms.
  • the chain is from 20 to 30 carbon atoms, suitably 22 to 30 carbon atoms.
  • the chain is from 22 to 28 carbon atoms.
  • dialkyl amphiphilic component refers to a component having both hydrophilic and lipophilic properties.
  • the dialkyl amphiphilic component comprises a large hydrophilic head group and a long hydrophobic tail comprising two alkyl groups.
  • the two alkyl groups are long chain alkyl groups.
  • the dialkyl amphiphilic component may be ionic, i.e. anionic or cationic, or non-ionic.
  • the anionic functionality can be provided by, for example, a phosphorus acid group or salt thereof or a sulphur acid group or salt thereof.
  • Suitable sulphur acid groups include sulphosuccinate: -OC(0)CH(S0 3 H)CH 2 C(0)0-, and alkoxylated sulphosuccinates:
  • dialkyl amphiphilic component is cationic
  • the cationic functionality may be provided by, for example, dialkyl dimethyl amines: -N + (CH3) 2 -, or imidazolines.
  • the nonionic hydrophilic functionality may be provided by, for example, esters of sorbitol, sorbitan, sucrose and polyglycerol, and alkoxylates thereof.
  • the dialkyl amphiphilic component is ionic. In another embodiment, the dialkyl amphiphilic component is anionic. In an embodiment, the anionic functionality is provided by a phosphorus acid group or a salt thereof. In another embodiment, the anionic functionality is provided by a phosphate group.
  • the dialkyl amphiphilic component is a salt.
  • the salt forming moiety is an alkali metal, particularly lithium, sodium or potassium, ammonium, including amine or hydroxyl-substituted amine, e.g. alkanoamine, onium, or amine, particularly alkylamine, especially tertiary alkylamine and hydroxy-substituted amine, e.g. alkanoamine, especially tertiary alkanoamine such as triethanolamine.
  • Salts can generally be made from free acid precursors by direct reaction with an appropriate base.
  • the salt forming moiety is an alkali metal.
  • the metal is sodium or potassium. In another embodiment it is potassium.
  • the dialkyl functionality of the amphiphilic component may be provided by any two suitable alkyl groups.
  • the alkyl groups are long chain alkyl groups.
  • the alkyl groups may be the same or different. In an embodiment, the alkyl groups are the same as each other.
  • Each alkyl group may be independently selected from the group including linear and branched alkyl groups.
  • the term alkyl refers to any saturated hydrocarbyl group which is a monovalent radical having the general formula C n H 2n +i.
  • each alkyl group is independently selected from the group consisting of CIO to C30 alkyl groups.
  • each alkyl group is independently selected from the group consisting of C12 to C26 alkyl groups.
  • each alkyl group is independently selected from the group consisting of C14 to C22 alkyl groups.
  • the alkyl groups are CI 6 alkyl groups.
  • the dialkyl amphiphilic component may optionally be present in combination with a monoalkyl amphiphilic component.
  • the monoalkyl amphiphilic component is a monoalkyl equivalent of the dialkyl amphiphilic component, i.e. the monoalkyl amphiphilic component is the same as the dialkyl amphiphilic component with one alkyl group substituted by H or a short chain alkyl group, for example, a methyl, ethyl or propyl group.
  • the dialkyl amphiphilic component is potassium dicetyl phosphate.
  • the monoalkyl amphiphilic component is potassium cetyl phosphate.
  • the lamellar membrane blend comprises a combination of potassium dicetyl phosphate and potassium cetyl phosphate.
  • the dialkyl amphiphilic component has a packing parameter, R, from about 0.25 to about 1.25. In another embodiment, the dialkyl amphiphilic component has a packing parameter, R, from about 0.3 to about 1.1. In yet another embodiment, the dialkyl amphiphilic component has a packing parameter, R, from about 0.5 to about 1.
  • the packing parameter, R, of the dialkyl amphiphilic component corresponds to a cylindrical or lamellar amphiphilic association structure. The packing parameter is calculated according to the formula:
  • v is the real volume of the dialkyl chain
  • a is the cross-sectional area of the amphiphilic component head group, i.e. the ionic or non-ionic group
  • 1 is the approximate length of the amphiphilic component hydrocarbon chain.
  • the dialkyl amphiphilic component is present in an amount from about 1 % to about 75% by weight, based on the total weight of the lamellar membrane blend. In another embodiment, the dialkyl amphiphilic component is present in an amount from about 5% to 50% by weight, based on the total weight of the lamellar membrane blend. In yet another embodiment, the dialkyl amphiphilic component is present in an amount from about 10% to 35% by weight, based on the total weight of the lamellar membrane blend. In a further embodiment, the dialkyl amphiphilic component is present in an amount from about 15% to 25% by weight, based on the total weight of the lamellar membrane blend.
  • the ester formed from a branched or straight chain fatty acid and a branched or straight chain fatty alcohol comprises a mixture of compounds having mono- and poly -branching in the acid and alcohol originating parts of the ester.
  • the fatty acid and fatty alcohol are alkyl branched.
  • the composition when the composition comprises an ester of a branched or straight chain fatty acid and a branched or straight chain fatty alcohol, the composition may further comprise a fatty acid.
  • the ester can be mixed.
  • the fatty acid component may be branched and the fatty alcohol may be straight chained.
  • the fatty acid component may be straight chained and the fatty alcohol may be branched.
  • both the acid and the alcohol may be branched.
  • both the acid and the alcohol may be straight chained.
  • the branched fatty acid component of the ester is a C 12 to C 3 6 branched or straight chain fatty acid, a C 12 to C30 branched or straight chain fatty acid, a CM to C26 branched or straight chain fatty acid, a CI 6 to C22 branched or straight chain fatty acid, or a CI 8 branched or straight chain fatty acid.
  • the branched fatty acid component of the ester is a CI 8 branched fatty acid.
  • the fatty acid component of the ester is branched, and in one embodiment is a C12 to C30 fatty acid, a C 14 to C26 fatty acid, a C 16 to C22, or a C 18 fatty acid.
  • Fatty acids suitable for use herein can be obtained from natural sources.
  • the fatty acids may be obtained from palm oil, rape seed oil, palm kernel oil, coconut oil, babassu oil, soybean oil, castor oil, sunflower oil, olive oil, linseed oil, cottonseed oil, safflower oil, tallow, whale or fish oils, grease, lard and mixtures thereof.
  • the fatty acids can also be synthetically prepared.
  • Relatively pure unsaturated fatty acids such as oleic acid, linoleic acid, linolenic acid, palmitoleic acid, and elaidic acid may be isolated, or relatively crude unsaturated fatty acid mixtures employed.
  • the fatty acid component of the ester may comprise a mixture of branched and linear fatty acids. In one embodiment, the fatty acid mixture comprises greater than about 70% of fatty acid.
  • the fatty acid mixture comprises from about 73% to about 95%, or about 77% to about 90%, or about 80% to about 85% by weight of branched fatty acids, and less than about 30%, or from about 5% to about 27%, or from about 10% to about 23%, or about 15% to about 20% by weight of linear fatty acids, based on the total weight of fatty acids present.
  • the fatty acid component of the ester may comprise a mixture of branched and linear fatty acids.
  • the fatty acid component of the ester is In one embodiment branched and comprises alkyl side chains (attached directly to a carbon atom of the longest linear chain) having on average less than 3, or less than 2.5, or in the range from 1.05 to 2, or from 1.1 to 1.4 carbon atoms, i.e. the side branches are predominantly methyl groups.
  • greater than 50%, or greater than 60%, or in the range from 70% to 97%, or in the range from 80% to 93% by number of the side-branched groups are methyl groups.
  • Suitable branched chain fatty acids for use in the ester of the lamellar membrane blend include iso-acids such as isostearic acid, isopalmitic acid, isomyristic acid, isoarachidic acid and isobehenic acid, neo-acids such as neodecanioc acid, and/or anti-iso acids.
  • the branched chain fatty acid is an iso-acid.
  • the fatty acid is isostearic acid.
  • the fatty alcohol component of the ester is a C12 to C36 alcohol, or a C 12 to C30 alcohol, or a C 14 to C26 alcohol, or a C 16 to C22, or a C 18 fatty alcohol.
  • all of the chains are branched.
  • the branched or straight chain fatty alcohol component of the ester is made from the fatty acid component of the ester. Therefore, the same preferences apply to the branched fatty alcohol component of the ester as to the branched fatty acid component of the ester.
  • the chain length of the fatty alcohol component of the ester is the same as the chain length of the fatty acid component of the ester.
  • a mixture of branched and linear fatty alcohols may be present in the fatty alcohol component of the ester.
  • the fatty alcohol mixture comprises greater than 70%, or in the range from 73% to 95%, or in the range from 77% to 90%, or in the range from 80% to 85% by weight of branched fatty alcohols, and less than 30%, or in the range from 5% to 27%, or 10% to 23%, or 15% to 20% by weight of linear fatty alcohols, both based on the total weight of fatty alcohol present.
  • Suitable branched fatty alcohols for use in the ester of the lamellar membrane blend include iso-alcohols such as isostearyl alcohol, isotetradecanol, isocetyl alcohol, isoarachidyl alcohol, isobehenyl alcohol and isolignoceryl alcohol; neo-alcohols such as neocapric alcohol; and/or anti-iso alcohols.
  • the branched chain fatty alcohol is an iso-alcohol.
  • the branched chain fatty alcohol is isostearyl alcohol.
  • the ester is an ester of a C I 6-22 branched fatty acid and a CI 6-22 branched fatty alcohol.
  • the branched fatty acid and branched fatty alcohol may comprise the same number of carbon atoms, or a different number of carbon atoms. In one embodiment, the branched fatty acid and branched fatty alcohol comprise the same number of carbon atoms.
  • the ester may comprise one or more variations selected from the group comprising mono- branched fatty acid and poly-branched fatty alcohol, mono-branched fatty acid and mono- branched fatty alcohol, poly-branched fatty acid and mono-branched fatty alcohol, and poly-branched fatty acid and poly-branched fatty alcohol.
  • the ester may be selected from this group by any suitable separation method.
  • the selected ester may be selected from a mixture of esters using a clathration method.
  • the ester is an ester of a C1 ⁇ 2 to C30 mono and/or poly-branched fatty acid and a Ci6 to C30 mono and/or poly branched fatty alcohol.
  • the ester comprises a C 18 mono- and/or poly-branched fatty acid and a C 18 mono- and/or poly-branched fatty alcohol. In one embodiment, the ester is isostearyl isostearate.
  • the ester is present in the lamellar membrane blend in an amount from about 1 % to 75% by weight, or from about 5% to about 50% by weight. In one embodiment from about 14% to about 35% by weight, or from about 18% to about 27% by weight, based on the total weight of the lamellar membrane blend.
  • the ester of a branched fatty acid and a branched fatty alcohol and the dialkyl amphiphilic component are present in the lamellar membrane blend at a ratio by weight of about 10: 1 to about 1 : 10, or about 5: 1 to about 1 :5, or about 2: 1 to about 1 :2.
  • the ester of a branched fatty acid and a branched fatty alcohol and the dialkyl amphiphilic component are present in the lamellar membrane blend at a ratio by weight of about 1.25: 1.
  • the lamellar membrane blend further comprises a fatty acid or a mixture thereof.
  • the fatty acid is a C12 to C36, or a C12 to C32, or a C16 to C30, or a CI 8 to C28 fatty acid, or a CI 8 to C24 carbon chain.
  • the fatty acid may be branched or linear. In one embodiment, the fatty acid is linear.
  • Fatty acids suitable for use in the lamellar membrane blend can be obtained from the same natural sources as the branched fatty acid component of the ester.
  • a mixture of fatty acids may be present in the lamellar membrane blend.
  • the fatty acid mixture comprises greater than 70%.
  • the fatty acid mixture comprises in the range from 73% to 95% w/w%, or about 77% to 90%, or about 80% to 85% by weight of linear fatty acids, and less than 30%, or in the range from 5% to 27%, or 10% to 23%, or 15% to 20% by weight of branched fatty acids, both based on the total weight of fatty acids present.
  • Suitable fatty acids for use in the lamellar membrane blend include lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid and cerotinic acid.
  • the fatty acid is selected from the group consisting of stearic acid, arachidic acid, behenic acid, lignoceric acid and cerotinic acid, or mixtures thereof. In another embodiment, the fatty acid is selected from arachidic acid, behenic acid and lignoceric acid, and mixtures thereof. In another embodiment, the fatty acid is stearic acid or behenic acid, or a mixture thereof. In one embodiment, the fatty acid is stearic acid. In another embodiment, the fatty acid is behenic acid.
  • the fatty acid or mixture thereof is present in the lamellar membrane blend in an amount from about 1% to about 75% by weight. In another embodiment the fatty acid or mixture thereof is present from about 5% to about 50% by weight. In another embodiment the fatty acid or mixture thereof is present from about 14% to about 35% by weight. In another embodiment the fatty acid or mixture thereof is present from about 18% to about 25% by weight, based on the total weight of the lamellar membrane blend.
  • the acid, or mixture of acids is present relative to the ester of a branched fatty acid and a branched fatty alcohol in a weight ratio of about 10: 1 to about 1 : 10.
  • the fatty acid, or mixture of fatty acids, and the ester of a branched fatty acid and a branched fatty alcohol are present in the blend at a weight ratio of about 1 : 1.
  • the fatty acid, or mixture of fatty acids is present in the lamellar membrane blend, the fatty acid, or mixture of fatty acids, is present relative to the dialkyl amphiphilic component at a weight ratio from about 10: 1 to about 1 : 10.
  • the acid, or mixture of acids, and the dialkyl amphiphilic component are present in the blend at a weight ratio of about 1.25 : 1.
  • the lamellar membrane blend further comprises a fatty alcohol, or a mixture thereof.
  • the fatty alcohol is a C12 to C36, or a C 12 to C28, or a C 14 to C26 or a C 16 to C24 fatty alcohol.
  • the chain length of the fatty alcohol is within 4 carbon atoms of the alkyl chain length of the dialkyl amphiphilic component.
  • the chain length of the fatty alcohol is within 2 carbon atoms of.
  • the chain length of the fatty alcohol is the same as the alkyl chain length of the dialkyl amphiphilic component.
  • the fatty alcohol may be branched or linear. In one embodiment, the fatty alcohol is linear.
  • a mixture of fatty alcohols may be present in the lamellar membrane blend.
  • the main component of the mixture of fatty alcohols is within 4 carbon atoms of, or within 2 carbon atoms of or is the same as the alkyl chain length of the dialkyl amphiphilic component.
  • the fatty alcohol mixture comprises greater than 70%, or is from about 73% to about 95%, or is about 77% to about 90%, or about 80% to about 85% by weight of linear fatty alcohols, and less than 30% by weight. In another embodiment, the fatty alcohol mixture in the range from about 5% to about 27%, or about 10% to about 23%, or about 15% to about 20% by weight of branched fatty alcohols, both based on the total weight of fatty alcohol present.
  • Suitable fatty alcohols for use in the lamellar membrane blend include but are not limited to, lauryl alcohol, tetradecanol, cetyl alcohol, stearyl alcohol, arachidyl alcohol, behenyl alcohol and lignoceryl alcohol, and mixtures thereof.
  • the fatty alcohol is selected from the group consisting of lauryl alcohol, tetradecanol, cetyl alcohol, stearyl alcohol, arachidyl alcohol and behenyl alcohol. In another embodiment, the fatty alcohol is selected from tetradecanol, cetyl alcohol, stearyl alcohol and behenyl alcohol. In yet another embodiment, the fatty alcohol is cetyl alcohol, or is behenyl alcohol, or a mixture of cetyl alcohol and behenyl alcohol. In one embodiment, the fatty alcohol or mixture thereof is present in the lamellar membrane blend in an amount from about 10% to about 85% by weight. In one embodiment from about 15% to about 70% by weight. In one embodiment from about 25% to about 55% by weight, or from about 30% to about 40% by weight, based on the total weight of the lamellar membrane blend.
  • the fatty alcohol, or mixture of fatty alcohols is present relative to the ester of a branched fatty acid and a branched fatty alcohol at a weight ratio from about 12: 1 to about 1 : 10, or from about 6: 1 to about 1 :5, or from about 4: 1 to about 1 : 1.
  • the fatty alcohol, or mixture of fatty alcohols, and the ester of a branched fatty acid and a branched fatty alcohol are present in the lamellar membrane blend at a weight ratio of about 1.6: 1.
  • the fatty alcohol, or mixture of fatty alcohols is present relative to the dialkyl amphiphilic component at a weight ratio of about 10: 1 to about 1 : 10. In one embodiment, the ratio is from about 5 : 1 to about 1 :5. In another embodiment, the ratio is from about 2: 1 to about 1 :2. In yet another embodiment, the fatty alcohol, or mixture of fatty alcohols, and the dialkyl amphiphilic component are present in the lamellar membrane blend at a weight ratio of about 2: 1.
  • the fatty alcohol, or mixture of fatty alcohols, and a fatty acid, or mixture of fatty acids are present in the blend, the fatty alcohol, or mixture of fatty alcohols, is present relative to the fatty acid, or mixture of fatty acids at a weight ratio from about 10: 1 to about 1 : 12. In one embodiment, the ratio is from about 5 : 1 to about 1 :6. In another embodiment, the ratio is from about 2: 1 to about 1 :4. In yet another embodiment, the fatty alcohol, or mixture of fatty alcohols, and the fatty acid, or mixture of fatty acids are present in the lamellar membrane blend at weight ratio of about 1 : 1.6.
  • the fatty alcohol, or mixture of fatty alcohols, and the fatty acid, or mixture of fatty acids may react to form an ester when both present in the lamellar membrane blend.
  • the ester, when formed is a cetyl behenate or cetyl stearate ester.
  • the lamellar membrane blend may be made in accordance with the disclosure of WO 2012/104604, Pennick et al, and US 2013/0324499, Pennick et al, whose disclosures are incorporated herein by reference.
  • the lamellar membrane blend is commercially available as a pastillated and/or flaked product from Croda International PLC.
  • a lamellar membrane blend for use in a lip protectant composition comprising (a) a dialkyl amphiphilic component and b) an ester of a branched fatty acid and a branched fatty alcohol.
  • a lamellar membrane blend for use in a lip protectant composition comprising (a) a dialkyl amphiphilic component, b) an ester of a branched fatty acid and a branched fatty alcohol, (c) a fatty acid and (d) a fatty alcohol.
  • the lamellar membrane blend comprises isostearyl isostearate, potassium dicetyl phosphate, behenic acid, cetyl alcohol and cetyl behenate.
  • the lamellar membrane blend comprises isostearyl isostearate, potassium dicetyl phosphate, behenic acid, cetyl alcohol, behenyl alcohol and cetyl behenate.
  • the lamellar membrane blend comprises isostearyl isostearate, potassium dicetyl phosphate, potassium cetyl phosphate, behenic acid, cetyl alcohol and cetyl behenate. This may be available commercially from Croda International PLC as DuraQuench IQ.
  • the lamellar membrane blend comprises isostearyl isostearate, potassium dicetyl phosphate, stearic acid, cetyl alcohol and cetyl stearate. In one embodiment, the lamellar membrane blend comprises isostearyl isostearate, potassium dicetyl phosphate, stearic acid, cetyl alcohol, behenyl alcohol and cetyl stearate. In another embodiment, the lamellar membrane blend comprises isostearyl isostearate, potassium dicetyl phosphate, potassium cetyl phosphate, stearic acid, cetyl alcohol and cetyl stearate. This may be available commercially from Croda International PLC as DuraQuench IQ-SA.
  • compositions of the invention may further comprise at least one dermatologically acceptable excipient.
  • the dermatologically acceptable excipient is selected from the group consisting of an antioxidant, a chelating agent, a preservative, a colorant, a sensate, a moisturizer, a humectant, a lip conditioning agent and a pH adjusting agent, and mixtures thereof.
  • the compositions of the invention are free or substantially free of a conventional emulsifier.
  • compositions of the invention may further comprise an antioxidant.
  • the antioxidant is a mixture of two or more antioxidants.
  • Antioxidants may protect the composition from oxidation (e.g. becoming rancid) and/or provide lip conditioning benefits upon application to the lips.
  • Tocopherol, tocopheryl acetate, some botanical butters, niacinamide, pterostilbene (trans-3,5-dimethoxy-4- hydroxystilbene) magnolol, and green tea extracts, alone or in combination thereof are exemplary natural product antioxidants suitable for use in the compositions.
  • antioxidants include ascorbic acid and esters thereof such as ascorbyl palmitate, butylated hydroxy toluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E TPGS, ethyl ferulate, ferulic acid, resveratrol, 2,2-dimethyl chroman (Lipochroman®) , singapine, tetrahydrocurcumin or other curcumin derivaties, hydroxytyrosol, Bis-Ethylhexyl Hydroxy dimethoxy Benzylmalonate (Ronacare AP ®), dimethylmethoxy chromanyl palmitate (Chromabright®) or a combination or mixture thereof.
  • ascorbic acid and esters thereof such as ascorbyl palmitate, butylated hydroxy toluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E TPGS, ethy
  • the antioxidant is tocopherol, or a mixture of tocopherol and ascorbyl palmitate. In another embodiment, the antioxidant is niacinamide.
  • the antioxidant is present in an amount from about 0.001 % to about 1 % by weight, based on the total weight of the composition.
  • compositions of the invention may further comprise a chelating agent.
  • the chelating agent is a mixture of two or more chelating agents.
  • Exemplary chelating agents include, but are not limited to, citric acid, glucuronic acid, sodium hexametaphosphate, zinc hexametaphosphate, ethylenediamine tetraacetic acid (EDTA), ethylenediamine disuccinic acid (EDDS), phosphorates, salts thereof, or a combination or mixture thereof.
  • the chelating agent is EDTA or a salt thereof, such as potassium, sodium or calcium salts of EDTA.
  • the chelating agent is ethylenediamine succinic acid or a salt thereof, such as potassium, sodium or calcium salts.
  • the chelating agent is trisodium ethylenediamine disuccinate.
  • the chelating agent is present in an amount from about 0.1 % to about 1% by weight, based on the total weight of the composition.
  • compositions of the invention may further comprise a preservative.
  • the preservative is a mixture of two or more preservatives.
  • Exemplary preservatives include, but are not limited to, benzyl alcohol, diazolidinyl urea or other substituted ureas and hydantoin derivatives, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, phenoxyethanol, sorbic acid, benzoic acid, salts thereof, or a combination or mixture thereof.
  • the preservative is present in an amount from about 0.01% to about 2% by weight.
  • the compositions of the invention are free of conventional preservatives.
  • the preservative is a combination of non-conventional preservatives, such as capryloyl glycine, and other glycols.
  • suitable glycols include, but are not limited to, caprylyl glycol and/or pentylene glycol.
  • these preservatives are present in an amount from about 0.5% to about 5% by weight, based on the total weight of the composition.
  • the capryloyl glycine is present in an amount from about 0.5% to about 2% by weight and the additional glycols can be added in amounts up to 5% by weight, based on the total weight of the composition.
  • the preservative is a combination of at least capryloyl glycine and caprylyl glycol in an amount from about 0.5% to about 2% by weight, based on the total weight of the composition.
  • compositions of the invention may further comprise a colorant that imparts color to the composition and/or lips.
  • a colorant that imparts color to the composition and/or lips.
  • the colorant should not be of an amount, particle size, and/or matrix that permits transfer of colorant to the lips during application.
  • a colorant that transfers and imparts color to the lips should be used.
  • Colorants include, for example, natural colorants such as plant extracts, natural minerals, carmine, synthesized and/or processed colorant materials such as iron oxides, synthetic dyes, organic compounds, lake colorants, and FDA certified colorants for use on the lips. The above list is not an exhaustive list of colorants and those of skill in the art may consider the use of other colorants. Formulations of colorants are commercially available.
  • An example of a commercially available colorant contains caprylic/capric triglycerides (59.5%), titanium dioxide (39.6%), castor oil phosphate (0.5%) and triethoxycaprylylsilane (0.4%).
  • the use of a colorant containing titanium dioxide can affect the stability of some sunscreens such as Avobenzone. It has been observed that colorants containing coated titanium dioxide can enhance the stability of Avobenzone.
  • compositions of the invention may further comprise a sensate.
  • a sensate is a composition that initiates a sensory perception such as heating or cooling, for example, when contacted with the skin and/or lips.
  • exemplary sensates include, but are not limited to, mint extracts, cinnamon extract and capsaicin.
  • Preferred sensates are derived from natural sources. However, synthetic sensates are within the scope of this invention.
  • Sensates typically have high potency and accordingly may yield significant impact at low levels.
  • the sensate is present in an amount from about 0.05% to about 5% by weight, based on the total weight of the composition.
  • compositions of the invention may further comprise a moisturizer.
  • exemplary moisturizers useful in the present compositions include, but are not limited to, pentylene glycol, butylene glycol, polyethylene glycol, sodium pyrrolidone carboxylate, a-hydroxy acids, ⁇ -hydroxy acids, polyhydric alcohols, ethoxylated and propoxylated polyols, polyols, polysaccharides, panthenol, hexylene glycol, propylene glycol, dipropylene glycol and sorbitol and mixtures thereof.
  • the moisturizer is present in an amount from about 0.5% to about 10% by weight, based on the total weight of the composition.
  • compositions of the invention may comprise an additional humectant i.e. in addition to glycerol.
  • additional humectants useful in the present compositions include, but are not limited to, betaine, sarcosine, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, sorbitol, glucose, and mixtures thereof.
  • the additional humectant is a mixture of pentylene glycol, caprylyl glycol and glucose.
  • the additional humectant is present in an amount from about 1% to about 15% by weight, based on the total weight of the composition.
  • compositions of the invention may comprise a lip conditioning agent.
  • lip conditioning agents include, but are not limited to, capryloyl glycine, ceramide-3 and phytosphingosine, and mixtures thereof.
  • the lip conditioning agent is present in an amount from about 0.001% to about 2% by weight, based on the total weight of the composition. pH adjusting agent
  • compositions of the invention may further comprise a pH adjusting agent.
  • the pH adjusting agent is a base. Suitable bases include amines,
  • the base is sodium hydroxide or potassium hydroxide.
  • the pH adjusting agent is an acid, an acid salt, or mixtures thereof.
  • the acid is selected from the group consisting of lactic acid, acetic acid, maleic acid, succinic acid, citric acid, benzoic acid, boric acid, sorbic acid, tartaric acid, edetic acid, phosphoric acid, nitric acid, ascorbic acid, dehydroacetic acid, malic acid, propionic acid, sulphuric acid and hydrochloric acid, or a combination or mixture thereof.
  • the pH adjusting agent is a buffer.
  • the buffer is selected from the group consisting of citrate/ citric acid, acetate/ acetic acid, phosphate/ phosphoric acid, propionate/ propionic acid, lactate/ lactic acid, carbonate/ carbonic acid, ammonium/ ammonia and edetate/ edetic acid, or a combination or mixture thereof.
  • compositions of the invention may further comprise a pharmaceutically acceptable active agent.
  • exemplary pharmaceutically active agents include, but are not limited to, an anti-inflammatory agent, an antibacterial agent, an antiviral agent, a nutritional agent, a sunscreen, a sun block, and mixtures thereof.
  • the pharmaceutically active agent is present in an amount from about 0.001 % to about 30% by weight, depending on the nature of the active agent, the condition being treated, and the composition.
  • the present lip protectant compositions enhance the effectiveness of the pharmaceutically active agent. This enhanced effectiveness may result from an improved solubility profile of the pharmaceutically active agent.
  • the pharmaceutically active agent is an anti-inflammatory agent.
  • anti-inflammatory agents are niacinamide and N-acylalkanolamines including, but not limited to, lactamide monoethanolamide (MEA), oleamide MEA, acetamide MEA (AMEA), palmitidyl MEA (PMEA), N-acetylphosphatidylethanolamine, N-acetyl- ethanolamine, N-oleoylethanolamine, N-linolenoylethanolamine, N-acylethanolamine, and N-acyl-2 -hydroxy-propylamine.
  • the N-acylalkanolamine is present in an amount from about 0.01% to about 2% by weight, based on the total weight of the composition.
  • the N-acylalkanolamine is present in an amount from about 0.01% to about 2% by weight, based on the total weight of the composition.
  • the N-acylalkanolamine is palmitidyl MEA (PMEA).
  • the anti-inflammatory agent is niacinamide.
  • the niacinamide is present in an amount from about 0.01 % to about 5% by weight, based on the total weight of the composition.
  • the pharmaceutically active agent is a sunscreen.
  • the sunscreen is at least one UVA sunscreen and/or at least one UVB sunscreen.
  • the sunscreen is a combination of at least one UVA sunscreen and at least one UVB sunscreen. Human lips are prone to sun damage when exposed to UVA and/or UVB radiation.
  • UVB radiation which is radiation in the wavelength range of 290 nm-320 nm, has traditionally been characterized as the radiation that causes sunburn.
  • UVB radiation can decrease enzymatic and non- enzymatic antioxidants in the skin and impair the natural protective mechanisms in the skin, thereby contributing to DNA damage and potentially skin cancer.
  • the dangers of UVA radiation which is radiation in the wavelength range of 320 nm to 400 nm, have only recently been recognized. Chronic exposure to UVA radiation can cause damage to gene P53 DNA, possibly leading to cancer.
  • UVA and UVB radiation are important for skin health and overall health more generally.
  • sunscreens particularly organic sunscreens
  • Some sunscreens including Avobenzone, useful for UVA protection have a very unpleasant taste. This unpleasant taste is not an issue for lotions that are applied to the body to protect body surfaces from sun damage, but become a significant problem when sunscreens are incorporated into lip protectant compositions as described herein.
  • sweeteners and/or flavorants have been used to cover or mask unpleasant tastes.
  • the sweetener and/or flavorant competes with the undesirable taste. While this may be successful in some applications, it is not satisfactory for masking the taste of the very strong and/or bitter flavors of organic sunscreens.
  • the flavor and/or sweetener may lack the persistence of taste over the entire time frame that the sunscreen remains on the lips, resulting in the evolution of a distasteful sensation after a period of time.
  • Coatings and forms of encapsulation are other approaches for taste-masking.
  • coatings and/or encapsulation may impact the effectiveness of the sunscreen.
  • coating or encapsulation of an unpleasant tasting material in a lip protectant is typically an even more difficult problem than taste-masking of an ingested material, as unlike ingested materials, the product is intended to stay on the lips for a period of several hours.
  • UV radiation ultraviolet radiation
  • melanin besides functioning as a broadband UV absorbent, has antioxidant and radical scavenging properties.
  • melanin found in mammals that give hair and skin its distinctive coloring, the brownish black eumelanin and the reddish yellow pheomelanin.
  • pheomelanin rather than protecting the skin against UV radiation, may actually contribute to UV -induced skin damage (Thody et al, J. Invest Dermat 97:340-344 (1991)).
  • Pheomelanin is also more concentrated on the lips in all individuals than eumelanin.
  • the shielding effect of melanin, especially eumelanin, is achieved by its ability to serve as a physical barrier that scatters UV radiation (UVR), and as an absorbent filter that reduces the penetration of UVR through the epidermis.
  • UVR UV radiation
  • the efficacy of melanin as a sunscreen was assumed to be about 1.5-2.0 sun protective factors (SPF); possibly as high as 4 SPF, implying that melanin absorbs 50% to 75% of UVR.
  • pheomelanin In contrast to eumelanin, pheomelanin is especially prone to photodegradation and is thought to contribute to the damaging effects of UVR because it can generate hydrogen peroxide and superoxide anions and might cause mutations in melanocytes or other cells. See Brenner et al, Photochem Photobiol, 84(3): p 539-549 (2008).
  • a topical composition which not only moisturizes but protects the lips from UVA and UVB radiation and reduces pheomelanin damage will provide additional benefits to the patient.
  • the present invention provides for a balanced UVA/SPF ratio of about 1 : 1 of sunscreen filters which is believed important to lip protection.
  • Another embodiment of the present invention is a method of protecting pheomelanin in the lips of a mammal from photodegradation, the method comprising applying to the lips of the mammal in need thereof an effective amount of a topical oil-in-water emulsion
  • composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount greater than about 12% by weight, based on the total weight of the composition;
  • a thickening agent comprising (i) a dialkyl amphiphilic component and (ii) an ester of a branched fatty acid and a branched fatty alcohol; and
  • composition is a lip protectant composition.
  • Another embodiment of the disclosure is a method of protecting the lips of a mammal against reactivation of herpes simplex virus, the method comprising applying to the lips of the mammal in need thereof an effective amount of a topical oil-in-water emulsion composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount greater than about 12% by weight, based on the total weight of the composition;
  • At least one lamellar membrane structure comprising (i) a dialkyl amphiphilic component and (ii) an ester of a branched fatty acid and a branched fatty alcohol;
  • composition is a lip protectant composition.
  • Yet another embodiment of the disclosure is a method of protecting the lips of a mammal, against a reoccurrence of cold sores, the method comprising applying to the lips of the mammal in need thereof an effective amount of a topical oil-in-water emulsion composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount greater than about 12% by weight, based on the total weight of the composition;
  • At least one lamellar membrane structure comprising (i) a dialkyl amphiphilic component and (ii) an ester of a branched fatty acid and a branched fatty alcohol;
  • UVA filters include, but are not limited to, Avobenzone (Parsol 1789), Bisdisulizole disodium (Neo Heliopan AP), Diethylamino hydroxybenzoyl hexyl benzoate (Uvinul A Plus), Ecamsule (Mexoryl SX), Menthyl anthranilate (Meradimate), oxybenzone, sulisobenzene and dioxybenzone, and mixtures thereof.
  • UVB filters include, but are not limited to, Amiloxate, 4-Aminobenzoic acid (PABA), Cinoxate, Ethylhexyl triazone (Uvinul T 150), Homosalate, 4-Methylbenzylidene camphor (Parsol 5000), Octyl methoxycinnamate (Octinoxate), Octyl salicylate (Octisalate), Padimate O (Escalol 507), Phenylbenzimidazole sulfonic acid (Ensulizole), Polysilicone- 15 (Parsol SLX) and Trolamine salicylate, and mixtures thereof.
  • PABA 4-Aminobenzoic acid
  • Cinoxate Cinoxate
  • Ethylhexyl triazone Uvinul T 150
  • Homosalate 4-Methylbenzylidene camphor
  • Octyl methoxycinnamate Octinoxate
  • Octyl salicylate Octisalate
  • UVA + UVB filters include, but are not limited to, Bemotrizinol (Tinosorb S),
  • Benzophenones 1 -12 Dioxybenzone, Drometrizole trisiloxane (Mexoryl XL), Iscotrizinol (Uvasorb HEB), Octocrylene, Oxybenzone (Eusolex 4360), Sulisobenzone and
  • exemplary sunscreens useful in the present invention include, but are not limited to, amino benzoic acid (about 15%), avobenzone (about 3%), the Cinnamates, such as but not limited to cinoxate (about 3%), and octyl methoxycinnamate (Octinoxate) (about 10%), the Salicylates, such as but not limited to homosalate (about 15%), meradimate (about 5%), octocrylene (about 10%), ethylhexyl salicylate (also known as octyl salicylate or octisalate) (about 5%), oxybenzone (about 6%), dioxybenzone (about 3%), Octyldimethyl PABA (Padimate O) (about 8%), p-amyldimethyl PABA (Padimate A) (about 3%), phenylbenzimidazole sulfonic acid (
  • NeoHeliopan AP (Bisdisulizole disodium or NeoHeliopan AP) (about 10%), drometrizole trisiloxane (silatriazole or Mexoryl XL) (about 15%), ethylhexyl dimethyl para-amino benzoic acid (about 8%), ethylhexyl methoxycinnamate (about 10%), ethylhexyl Triazone (Uvinul T 150) (about 5%), isoamyl p-methoxycinnamate (about 10%), 4-methylbenzylidene camphor (about 10%), methylene bis-benzotriazolyl tetramethylbutylphenol (Bisoctrizole or Tinosorb M) (about 10%), PEG-25 paramainobenzoic acid (about 5%),
  • phenylbenziamido methylbenzylidene camphor (about 6%), diisopropyl methyl cinnamate (about 10%), dimethoxyphenyl-[l-(3,4)-4,4-dimethyl] l,3 pentanedione (about 7%), ethylhexyl dimethyloxy benzylidene dioxoimidazoline propionate (about 3%), ferulic acid (about 10%), glyceryl ethylhexanoate dimethoxycinnamate (about 10%), glycerol para- aminobenzoic acid (about 10%), phenylbenzimidazole sulfonic acid (about 3%) and Parsol SLX (benzylidene malonate polysiloxane), and mixtures thereof.
  • the amounts listed in the preceding list are for each sunscreen individually. In some embodiments in which a combination or mixture of sunscreens is used, the total combined amount of a sunscreen may be less
  • Cinamates include but are not limited to octinoxate, cinoxate, and isoamyl p-methoxy cinnamate, and glyceryl ethylhexanoate dimethoxycinnamate.
  • Salicylates include but are not limited to octisalate, homosalate, and trolamine salicylate.
  • Benzophenones includes oxybenzone, sulisobenzone, and dioxybenzone.
  • PABA and derivatives includes PABA (p-aminobenzoic acid), Octyldimethyl PABA (Padimate O), p-amyldimethyl PABA (Padimate A), Ethyl
  • Avobenzone, and benzophenones, as well as some other sunscreens, are photo unstable. Therefore these sunscreens are frequently combined with other sunscreens or stabilizers to increase the photostability of the final product.
  • Some suitable photo stabilizers also referred to herein as boosters include, but are not limited to Octocrylene, Diethylhexyl 2,6- naphthalate, and Diethylhexyl syringylidene malonate.
  • the photostabilizer is Diethylhexyl syringylidene malonate.
  • a single sunscreen may be used in a lip protectant composition
  • typically a combination of sunscreens will be used as each sunscreen has a characteristic wavelength range in which it absorbs UV radiation (UVR) and typically that range is less than the entire range for which protection is desired.
  • UVR UV radiation
  • use of a combination of sunscreens provides protection over a wider range of wavelengths.
  • efficacy of protection is also related to the amount of sunscreen. As regulatory agencies limit the amount of each sunscreen that can be used, the use of multiple sunscreens improves the SPF while maintaining regulatory compliance.
  • Organic sunscreens and their efficacious wavelength range are as follows: amino benzoic acid (260 nm-313 nm, about 5% to about 15%); padimate O (290 nm-315 nm, about 1.4% to about 8%); dioxybenzone (260 nm-380 nm, about 1% to about 3%); oxybenzone (270 nm-350 nm, about 2% to about 6%); sulisobenzone (260 nm- 375 nm, about 5% to about 10%); cinoxate (270 nm-328 nm, about 1% to about 3%); octocrylene (250 nm-360 nm, about 7% to about 10%); Avobenzone (320 nm-400 nm, about 1% to about 3%); octyl salicylate (280 nm-320 nm, about 3% to about 5%);
  • homosalate (295 nm-315 nm, about 4% to about 15%); trolamine salicylate (260 nm-320 nm, about 5% to about 12%); octinoxate (290 nm-320 nm, about 2% to about 7.5%).
  • At least two sunscreens are used where the first sunscreen has an efficacious wavelength range that includes about 280 nm to about 315 nm and the second sunscreen has an efficacious wavelength range that includes about 315 nm to about 400 nm.
  • the at least one UVA sunscreen is Avobenzone. In an embodiment, the at least one UVA sunscreen is avobenzone and the composition further comprises a similiter stabilizer, which is diethylhexyl syringylidene malonate. In another embodiment, the at least one UVB sunscreen is ethylhexyl salicylate (Octisalate). In yet another embodiment, the at least one UVB sunscreen is ethylhexyl salicylate (Octisalate) and the composition further comprises a sunfilter stabilizer, which is diethylhexyl syringylidene malonate.
  • the sunscreen is a combination of avobenzone and ethylhexyl salicylate (Octisalate). In another embodiment, the sunscreen is a combination of avobenzone and ethylhexyl salicylate (Octisalate), and the composition further comprises a sunfilter stabilizer, which is diethylhexyl syringylidene malonate.
  • the UVA/SPF protection ratio is from about 1 : 1 to about 1 :3. In another embodiment, the UVA/SPF protection ratio is about 1 : 1. To determine this number, in vivo testing is performed for the SPF value and in vitro testing is performed for the UVA value. The UVA number is divided by the SPF number to obtain the protection value, for instance, a UVA value of 10 and a SPF of 10 would yield a 1/1 value.
  • the avobenzone is present in an amount from about 2% to about 3% by weight, based on the total weight of the composition. In another embodiment, octisalate is present in an amount from about 4% to about 5% by weight, based on the total weight of the composition. In yet another embodiment, avobenzone is present in an amount from about 2% to about 3% by weight and octisalate is present in an amount from about 4% to about 5% by weight, based on the total weight of the composition. In another embodiment, avobenzone is present in an amount of about 2.75% and octisalate is present in an amount of about 4.5%, based on the total weight of the composition.
  • avobenzone is desirable for UVA protection as it is efficacious in the range of about 320 nm to 400 nm, a range in which most sunscreens provide limited to no protection.
  • avobenzone has particularly offensive organoleptic properties.
  • the present invention provides not only for the use of efficacious amounts of avobenzone in a lip protectant but in a composition which covers the offensive taste.
  • inorganic sunscreens such as titanium dioxide and/or zinc oxide, for example.
  • inorganic sunscreens such as titanium dioxide and/or zinc oxide, for example.
  • Such compounds may be used in amounts from about 2% to about 25% by weight, with higher amounts providing higher levels of protection.
  • inorganic sunscreens are in one embodiment used in combination with organic sunscreens to obtain efficacious protection.
  • compositions of the invention have a comparatively high water content (relative to the prior art) and therefore enhance the moisturization of the lips. They are also generally free of conventional emulsifiers and thus are capable of restoring or repairing the skin lipid barrier of the lips. Furthermore, in some embodiments, the compositions protect the lips from UV damage. More specifically, the compositions are formulated to protect the lips from UVA radiation and thus assist in preventing photodegradation of
  • the U. S. Skin Protectant monograph requires a high level of glycerin, e.g. 20% to 45% to be compliant with the monograph and be considered a lip protectant. This is very difficult to achieve in a formulation which is not tacky and still consumer friendly to use.
  • the monograph can be found at
  • compositions comprise from about 20% to about 40% glycerin, they are in accordance with the monograph requirements.
  • the invention provides a topical oil-in-water emulsion composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount from about 12% to about 40% by weight, based on the total weight of the composition;
  • the invention provides a topical oil-in-water emulsion composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount from about 12% to about 40% by weight, based on the total weight of the composition;
  • At least one lamellar membrane structure comprising (i) a dialkyl amphiphilic component and (ii) an ester of a branched fatty acid and a branched fatty alcohol;
  • composition is a lip protectant composition.
  • the invention provides a topical oil-in-water emulsion composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount from about 12% to about 40% by weight, based on the total weight of the composition;
  • At least one lamellar membrane structure comprising (i) a dialkyl amphiphilic component, (ii) an ester of a branched fatty acid and a branched fatty alcohol, (iii) a fatty acid and (iv) a fatty alcohol; and
  • composition is a lip protectant composition.
  • the invention provides a topical oil-in-water emulsion composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount from about 12% to about 40% by weight, based on the total weight of the composition;
  • At least one lamellar membrane structure comprising (i) a dialkyl amphiphilic component, (ii) an ester of a branched fatty acid and a branched fatty alcohol, (iii) a fatty acid and (iv) a fatty alcohol; and
  • composition (e) a combination of at least one UVA sunscreen and at least one UVB sunscreen, and wherein the UVA sunscreen has a UVA/SPF protection ratio of about 1 : 1 ; and wherein the composition is a lip protectant composition.
  • the invention provides a topical oil-in-water emulsion composition comprising:
  • At least one lamellar membrane structure comprising (i) a dialkyl amphiphilic component and (ii) an ester of a branched fatty acid and a branched fatty alcohol;
  • the composition may optionally comprise at least one dermatologically acceptable excipient selected from an antioxidant, a chelating agent, a preservative, a colorant, a sensate, a moisturizer, a humectant, a pH adjusting agent, a pharmaceutically acceptable agent, and combinations and mixtures thereof.
  • at least one dermatologically acceptable excipient selected from an antioxidant, a chelating agent, a preservative, a colorant, a sensate, a moisturizer, a humectant, a pH adjusting agent, a pharmaceutically acceptable agent, and combinations and mixtures thereof.
  • the invention provides a method for moisturizing, and protecting, repairing, or restoring the skin lipid barrier of the lips of a mammal, the method comprising applying to the lips of the mammal in need thereof a therapeutically effective amount of a topical oil-in-water emulsion composition comprising:
  • a discontinuous oil phase (b) a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount greater than about 12% by weight, based on the total weight of the composition;
  • At least one lamellar membrane structure comprising (i) a dialkyl amphiphilic component and (ii) an ester of a branched fatty acid and a branched fatty alcohol;
  • composition is a lip protectant composition.
  • the invention also provides for the use of a topical oil-in-water emulsion composition
  • a topical oil-in-water emulsion composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount greater than about 12% by weight, based on the total weight of the composition;
  • At least one lamellar membrane structure comprising (i) a dialkyl amphiphilic component and (ii) an ester of a branched fatty acid and a branched fatty alcohol; in the manufacture of a lip protectant composition for moisturizing, and protecting, repairing, or restoring the skin lipid barrier of the lips of a mammal.
  • the invention further provides for the use of a topical oil-in-water emulsion composition
  • a topical oil-in-water emulsion composition comprising:
  • a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount greater than about 12% by weight, based on the total weight of the composition;
  • At least one lamellar membrane structure comprising (i) a dialkyl amphiphilic component and (ii) an ester of a branched fatty acid and a branched fatty alcohol;
  • composition is a lip protectant composition, for moisturizing, and protecting, repairing, or restoring the skin lipid barrier of the lips of a mammal.
  • the invention further provides for the use of a topical oil-in-water emulsion composition
  • a topical oil-in-water emulsion composition comprising:
  • a discontinuous oil phase (b) a continuous aqueous phase comprising water and glycerin, wherein the glycerin is present in an amount greater than about 12% by weight, based on the total weight of the composition;
  • composition is a lip protectant composition, for protecting lips with broad spectrum protection of a UVA and UVB sunscreen, and enriched in UVA protection.
  • compositions of the present invention improves the skin barrier function and conveys numerous additional therapeutic effects to a mammal to which the compositions are applied.
  • the compositions described herein provides moisturization to the lips. Adding the substantial amount of glycerin in the aqueous phase is believed to not render the composition feel tacky or sticky in comparison to other compositions with less glycerin present.
  • compositions of the invention are applied to the lips at a frequency consistent with the condition of the lips. For example, where the lips are irritated and in need of repair, more frequent application may be required. Alternatively, where the lips are not irritated and the composition is being applied to merely protect the barrier function of the lips, less frequent application may be possible.
  • applying refers to any method which, in sound medical or cosmetic practice, delivers the topical composition to the lips of a subject in such a manner so as to provide a positive effect on a dermatological disorder, condition, or appearance.
  • the compositions are in one embodiment administered such that they cover the entire lips.
  • an "effective amount” or a “therapeutically effective amount” refers to an amount of a composition or component thereof sufficient enough to have a positive effect on the area of application. Accordingly, these amounts are sufficient to modify the skin disorder, condition, or appearance to be treated but low enough to avoid serious side effects, within the scope of sound medical advice. A therapeutically effective amount will cause a substantial relief of symptoms when applied repeatedly over time. Effective amounts will vary with the particular condition or conditions being treated, the severity of the condition, the duration of the treatment, and the specific components of the composition being used.
  • the term "effective amount" of a sunscreen is an amount of sunscreen sufficient to provide measurable protection from solar radiation as determined by having a measurable Sun Protection Factor (SPF) value and/or UVA protection value.
  • SPF Sun Protection Factor
  • SPDF Sun Protection Factor
  • UVB UVB energy required to produce a minimal erythema dose on sunscreen treated skin divided by the UVB energy required to produce a minimal erythema dose on unprotected skin.
  • treatment in reference to a condition means: (1) to ameliorate or prevent the condition or one or more of the biological manifestations of the condition, (2) to interfere with (a) one or more points in the biological cascade that leads to or is responsible for the condition or (b) one or more of the biological manifestations of the condition, (3) to alleviate one or more of the symptoms or effects associated with the condition, or (4) to slow the progression of the condition or one or more of the biological manifestations of the condition.
  • prevention of a condition includes prevention of the condition.
  • prevention is not an absolute term. In medicine, “prevention” is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or severity of a condition or biological manifestation thereof, or to delay the onset of such condition or biological manifestation thereof.
  • compositions any inactive ingredient present in the herein described compositions.
  • Each excipient must be compatible with the other ingredients of the lip protectant composition when commingled such that interactions which would substantially reduce the efficacy of the composition when administered to an individual and interactions which would result in compositions that are not pharmaceutically or cosmetically acceptable are avoided.
  • each excipient must be of sufficiently high purity to render it pharmaceutically or cosmetically acceptable.
  • a lip protectant is a semisolid composition for application to the lips that provides protective, restorative and/or moisturizing properties.
  • These compositions include creams, and lip balms in a stick presentation, as well as soft lip balms such as, for example, those dispensed from jars, pots or tubes.
  • stick lip balm means a lip balm that can be formed into a stick that is extensible and retractable from a container and is sufficiently robust to substantially retain the stick shape under typical commercial conditions of shipping, storage and use.
  • Lip balms are an over-the-counter drug defined as a "drug product that relieves and prevents dryness or chapping of the exposed surface of the lip".
  • lipstick means a waxy stick product containing pigment which is transferable to the lips to impart a visible color. Lipsticks may be cosmetics or lip treatments.
  • a lipstick is a lip treatment if, in addition to imparting color, it provides protective and/or moisturizing properties, and/or a beneficial agent and/or a sunscreen and/or a
  • organic sunscreen means a compound or mixture of compounds that can protect human skin from UVA and/or UVB radiation and is the class of compounds classified by those skilled in the art of chemistry as organic chemicals.
  • inorganic sunscreen means a compound or mixture of compounds that can protect human skin from UVA and/or UVB radiation and is the class of compounds classified by those skilled in the art of chemistry as inorganic chemicals.
  • exemplary inorganic sunscreens include, but are not limited to, zinc oxide and titanium dioxide.
  • salts thereof refers to salts that are pharmaceutically acceptable.
  • Such salts include: (1) acid addition salts, formed with acids such as, for example, acetic acid, benzoic acid, citric acid, gluconic acid, glutamic acid, glutaric acid, gly colic acid, hydrochloric acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, phosphoric acid, propionic acid, sorbic acid, succinic acid, sulfuric acid, tartaric acid, naturally and synthetically derived amino acids, and mixtures thereof; or (2) salts formed when an acidic proton present in the parent compound is either (i) replaced by a metal ion e.g.
  • % refers to the percentage by weight of the total composition, unless otherwise specified. All percentages are based on the percent by weight of the final composition prepared unless otherwise indicated and all totals equal 100% by weight.
  • wt/wt or "by weight”, unless otherwise indicated, means the weight of a given component or specified combination of components to the total weight of the composition expressed as a percentage.
  • a designation that a substance is a semisolid, should be taken to mean the physical state of the substance in the temperature range of about 20°C to about 40°C.
  • phytosterol refers to plant sterols and plant stanols. Plant sterols are naturally occurring cholesterol-like molecules found in all plants, with the highest concentrations occurring in vegetable oils. Plant stanols are hydrogenation compounds of the respective plant sterols. Phytosterols are natural components of common vegetable oils.
  • sensitive skin refers to the degree of skin irritation or skin inflammation, as exemplified by parameters in suitable assays for measuring sensitivity, inflammation or irritation.
  • Substantially free of a specified component refers to a composition with less than about 1% by weight of the specified component.
  • Free of a specified component refers to a composition where the specified component is absent.
  • mamal includes, but is not limited to, humans, including pediatric, adult and geriatric patients.
  • the present formulations do not include as a necessary excipient a traditional surfactant.
  • a traditional surfactant As such this is meant to mean anionic, cationic, non-ionic and zwiterionic surfactants.
  • Traditional anionic surfactants include ammonium lauryl sulfate, sodium lauryl sulfate (sodium dodecyl sulfate, SLS, or SDS), and the related alkyl-ether sulfates sodium laureth sulfate (sodium lauryl ether sulfate or SLES), docusate (dioctyl sodium sulfosuccinate), perfluorooctanesulfonate (PFOS), alkyl-aryl ether phosphates and alkyl ether phosphates.
  • PFOS perfluorooctanesulfonate
  • CTC cetrimonium bromide
  • CPC cetylpyridinium chloride
  • BAC benzalkonium chloride
  • Traditional zwiterionic surfactants include cocamidopropyl hydroxy sultaine, and cocamidopropyl betaine.
  • Non-ionic surfactants include polyethylene glycol alkyl ethers (such as Brij); polypropylene glycol alkyl ethers; glucoside alkyl ethers, such as decyl glucoside, lauryl glucoside, and octyl glucoside; polyethylene glycol octylphenyl ethers, such as Triton X-100; polyethylene glycol alkylphenyl ethers, such as Nonoxynol-9; Glycerol alkyl esters, such as glyceryl laurate; polyoxy ethylene glycol sorbitan alkyl esters, such as the polysorbates; the sorbitan alkyl esters, such as the spams; and the block copolymers of polyethylene glycol and polypropylene glycol, e.g. the poloxamers.
  • polyethylene glycol alkyl ethers such as Brij
  • polypropylene glycol alkyl ethers such as de
  • a lip protectant composition having the following formulation illustrates the invention:
  • the composition is prepared in two key steps.
  • a blend (pastilles) having the lamellar membrane structure* composition is prepared.
  • the pastilles are formed by, for example, combining behenic acid, cetyl alcohol, isostearyl isostearate, cetyl behenate and dicetyl phosphate to form a blend.
  • the blend is neutralized with potassium hydroxide, the residual water removed and then the blend pastillated to form pastilles.
  • the lamellar membrane blend is available as a pastillated and/or flaked product from Croda
  • the blend is added to the composition during the formulation of an oil-in- water emulsion to give the final composition as follows:
  • Phase 1 (Aqueous):
  • Phase 4 (Lamellar membrane structure component):
  • Phase 1 and Phase 2 are first heated to 83 °C (+/- 3deg C) for production. Phase 2 is then slowly added to Phase 1 and the mixture is continuously stirred. The combined Phases are then homogenized for a minimum of 5 minutes at 15000 RPM with a hand held homogenizer. The combined phases are allowed to cool to 65°C with continuous stirring. Phase 3 is then added to the combined Phases 1 and 2 and mixed for a minimum of 5 minutes. The combined Phases (1, 2, and 3) are then cooled to 35°C with continuous stirring in a water bath. Phase 4 is then added to Phases 1, 2, and 3 with continuous stirring. The mixture is then homogenized again for a minimum of 10 minutes at 12000 RPM.
  • the lip protectant composition thus produced is deaerated and allowed to rest overnight prior to further analysis. (Note: the deaeration step is required for small scale manufacture since the system is not under vacuum and so air can be beaten into the system and affect the ability of emulsifiers to orientate in oil/water vs air/water. Removal of the air creates a system similar to that produced on the larger scale mixer such as a Beko mixer).
  • Example 2 Determining the protective activity against UVB-induced DNA damage, apoptosis and inflammation using reconstructed human epidermis (EpiDerm)
  • reconstructed human epidermis (EpiDerm, EPI-200, made of normal human epidermal keratinocytes, MatTek, Ashland, MA) are placed into media (EPI-100-ASY, 1.0 ml/well of 6-well plates) and incubated overnight at 37°C / 5% CC .
  • the media is replenished with fresh culture media prior to study.
  • a lip balm formulation with UV filters (Invention) and one without UV filters (placebo) are applied topically (2 and 10 mg/cm 2 , using positive displacement pipette tip for formulation) and then gently massaged into the skin equivalents (-20 rotations) using the rubber side of a plunger of 1 ml syringe.
  • Distilled H 2 0 serves as an untreated control, and distilled H 2 0 plus UVB irradiation serves as a UVB control.
  • the EpiDerm tissues are transferred to a sterile 6-well plate containing 1 ml of DPBS per well and then exposed to UVB at 150 mJ/cm 2 .
  • the Newport Solar Simulator System Power unit 69920, and Lamp 91192-1000, Newport Corporate, Irvine, CA
  • the Newport Solar Simulator System is used as the UVB emitter to achieve a UVB irradiation of 150mJ/cm 2 .
  • Measurement of the irradiation is taken using an ILT-1400 Handheld, Portable Radiometer /Photometer (International Light Technologies, Inc., Peabody, MA) with a UVB detector (SEL240/T2ACT5, 235 - 307 nm, International Light Technologies, Inc.). After UVB irradiation, EpiDerm tissues are transferred back to the 6-well plate containing media and incubated at 37°C/5% CO2 for 6 hours. At the end of the incubation (6 hr post UVB irradiation), culture media is collected for the measurement of IL-6, IL-8, and TNF-a concentration by MagPix (Millipore,
  • HCYTOMAG-60K HCYTOMAG-60K
  • PGE 2 concentration by ELISA R&D Systems, SKGE004B
  • the EpiDerm tissues are harvested and placed in 10% formalin for histological processing including paraffin embedding, sectioning, immunohistological analyses of DNA damage (cyclobutane pyrimidine dimers, CPDs) and apoptosis (cleaved caspase-3, CC3).
  • Gingival oral mucosal equivalents (EpiGingival, GIN- 100, MatTek, Ashland, MA) use normal human oral keratinocytes (NHOK) to differentiate into tissues with a comified, gingival phenotype. Therefore, EpiGingival might better replicate the characteristics of lip skin and will be used to evaluate the photoprotective effect of lip balm formulations.
  • EpiGingival equivalents Upon receipt, EpiGingival equivalents are placed into media (GIN-100-MM, 1.0 ml/ well of 6- well plates) and incubated overnight at 37°C / 5% CO2. The media is replenished with fresh culture media prior to study.
  • the lip balm with SPF (Invention) and without SPF (placebo) are applied topically ( ⁇ 4 mg/cm 2 , using positive displacement pipette tip for formulation) and then gently massaged into the skin equivalents (-20 rotations) using the rubber side of a plunger of 1 ml syringe.
  • Distilled H 2 0 serves as an untreated control, and distilled H 2 0 plus UVB irradiation serves as a UVB control.
  • the EpiGingival tissues are transferred to a sterile 6-well plate containing 1 ml of DPBS per well and then exposed to UVB at 150 mJ/cm 2 as described in Example 2.
  • EpiGingival tissues are transferred back to the 6-well plate containing media and incubated at 37°C/5% CO2 for 6 hours.
  • culture media is collected for the measurement of 11-6, IL-8, and TNF-a concentration by MagPix (Millipore, HCYTOMAG-60K) and PGE 2 concentration by ELISA (R&D Systems, SKGE004B).
  • EpiGingival tissues are harvested and placed in 10% formalin for histological processing including paraffin embedding, sectioning, immunohistological analyses of DNA damage (cyclobutane pyrimidine dimers, CPDs) and apoptosis (cleaved caspase-3, CC3).
  • Example 4 Determining the protective activity against UVA-induced DNA damage, apoptosis and inflammation using Full thickness skin equivalents (EpiDerm FT )
  • EpiDerm FT System consists of normal, human-derived epidermal keratinocytes and dermal fibroblasts which have been cultured to form a multilayered, highly differentiated model of the human dermis and epidermis.
  • EpiDerm FT refers to full thickness epidermal equivalents.
  • EpiDerm FT (EFT-400, MetTek) will be used for the assessment of UVA-induced skin damage and photoprotective activity of lip balm formulations.
  • EpiDerm FT is placed into media (EFT-400-MM, 1.0 ml/well of 6-well plates) and incubated overnight at 37°C / 5% CO2. The media is replenished with fresh culture media prior to study.
  • the lip balm with SPF (Invention) and without SPF (placebo) are applied topically (10 mg/cm 2 , using positive displacement pipette tip for formulation) and then gently massaged into the skin equivalents (-20 rotations) using the rubber side of a plunger of 1 ml syringe.
  • Distilled H 2 0 serves as an untreated control, and distilled H 2 0 plus UVA irradiation serves as a UVA control.
  • the EpiDerm FT tissues were transferred to a sterile 6-well plate containing 1 ml of DPBS per well and then exposed to UVA at 30-50 J/cm 2 as indicated.
  • the Newport DS-101103 UV Solar Simulator with UV-A-F filter (Sol-UV-A-F ) (Newport Corporate) is used as the UVA emitter to achieve a UVA irradiation of 30-50 J/cm 2 . Measurement of the irradiation is taken using an ILT-1400-A radiometer/photometer with a UVA probe (SSL001 A, international light technologies, Inc.).
  • EpiDerm FT tissues are transferred back to the 6-well plate containing media and incubated at 37°C/5% CO2 for 6 hours.
  • culture media is collected for the measurement of IL-8, and TNF-a concentration by MagPix (Millipore, HCYTOMAG-60K) and PGE 2 concentration by ELISA (R&D Systems, SKGE004B).
  • the EpiDerm FT tissues are harvested and placed in 10% formalin for histological processing including paraffin embedding, sectioning, immunohistological analyses of DNA damage (8-hydroxy-2' -deoxyguanosine, 80HdG) and apoptosis (cleaved caspase-3, CC3).
  • Example 5 Determining the protective activity against UVA-induced tissue damage using gingival mucosal equivalent (EpiGingival)
  • Gingival oral mucosal equivalents (EpiGingival, GIN- 100, MatTek, Ashland, MA) are used for the assessment of the protective effect of a lip balm formulation against UVA radiation.
  • the gingival equivalents were maintained as described in Example 4.
  • the lip balm with UV filters (Invention) and without UV filters (placebo) are applied topically ( ⁇ 4 mg/cm 2 , using positive displacement pipette tip for formulation) and then gently massaged into the skin equivalents (-20 rotations) using the rubber side of a plunger of 1 ml syringe.
  • the EpiGingival tissues are transferred to a sterile 6-well plate containing 1 ml of DPBS per well and then exposed to UVA at 30- 50 J/cm 2 as described in Example 4. Sham irradiated EpiGingival equivalents are used as sham control. After UVA irradiation, EpiGingival equivalents are transferred back to the 6-well plate containing media and incubated at 37°C/5% CO2 for 28 hours. At the end of the incubation (28 hr post UVA irradiation), culture media are PGE 2 concentration by ELISA (R&D Systems, SKGE004B).
  • EpiGingival equivalents are harvested and placed in 10% formalin for histological processing including paraffin embedding, sectioning, immunohistological analyses of DNA damage (8-hydroxy-2' -deoxyguanosine, 80HdG) and apoptosis (cleaved caspase-3, CC3).
  • EpiGingival equivalents are also pretreated with lip balm with UV filters for 1 hr, then irradiated with UVA at 30 J/cm2, followed by UVB radiation at 150 mJ/cm 2 .
  • Two accepted Tack Test methods include the Probe Tack Method and the Rolling Ball Method as both defined in the Unites States Pharmacopeial Convention, Interim Revision Announcement, November 1, 2013 whose disclosure is incorporated herein by reference.
  • Probe Tack Method uses a Malvern Kinexus Rheometer to Measure Tackiness.
  • the Basic Method Parameters which may be modified as needed are:
  • Rheometer lowers upper cone to compress sample to 0.15mm target gap, waits 0.5 sec and then quickly pulls away from sample while measuring force vs time to generate a plot.

Abstract

L'invention concerne une émulsion huile dans eau destinée à un usage topique, présentant des propriétés d'hydratation et de protection, de réparation ou de restauration de la barrière lipidique de la peau des lèvres d'un mammifère, et est une composition d'émulsion huile dans eau destinée à un usage topique comprenant : (a) une phase huileuse discontinue; (b) une phase aqueuse continue comprenant de l'eau et de la glycérine, la glycérine représentant une quantité supérieure à environ 12 % pds/pds; (c) un agent épaississant; et d) au moins une structure membranaire lamellaire comprenant (i) un composant amphiphile dialkylique et (ii) un ester d'un acide gras ramifié et d'un alcool gras ramifié; et la composition est une composition destinée à la protection des lèvres.
PCT/US2016/058583 2015-10-29 2016-10-25 Nouvelles formulations WO2017074895A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562247784P 2015-10-29 2015-10-29
US62/247,784 2015-10-29

Publications (1)

Publication Number Publication Date
WO2017074895A1 true WO2017074895A1 (fr) 2017-05-04

Family

ID=58630678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/058583 WO2017074895A1 (fr) 2015-10-29 2016-10-25 Nouvelles formulations

Country Status (1)

Country Link
WO (1) WO2017074895A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2678188C1 (ru) * 2018-08-31 2019-01-24 Общество с ограниченной ответственностью "Криопротект" Средство защиты кожи от холодового повреждения
WO2022129161A1 (fr) * 2020-12-16 2022-06-23 L'oreal Composition, en particulier composition cosmétique, à effet de flou

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6663853B2 (en) * 2000-11-30 2003-12-16 Blistex Inc. Lip care moisturizer
US20070065392A1 (en) * 2005-07-12 2007-03-22 L'oreal Cosmetic composition with an amphiphilic lipid phase
US20090017147A1 (en) * 2005-01-14 2009-01-15 Sederma Cosmetic or Dermopharmaceutical Composition Comprising an Euglena Extract
US20100190740A1 (en) * 2008-12-18 2010-07-29 L'oreal Oil-in-water emulsion
US20120225143A1 (en) * 2011-03-03 2012-09-06 Ranir, Llc Cold sore formulation and related method of manufacture
US20130164229A1 (en) * 2011-12-22 2013-06-27 Mary Kay Inc. Lip formulation
US20130324499A1 (en) * 2011-02-05 2013-12-05 Croda International Plc Moisturiser blend
WO2015113307A1 (fr) * 2014-01-30 2015-08-06 Dow Corning Corporation Compositions pour application sur la peau pour réduire l'adhésion de particules de pollution sur la peau et leurs procédés de préparation
US20150272861A1 (en) * 2014-03-28 2015-10-01 Nusil Technology Llc Dispersions containing encapsulated materials and compositions using same

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6663853B2 (en) * 2000-11-30 2003-12-16 Blistex Inc. Lip care moisturizer
US20090017147A1 (en) * 2005-01-14 2009-01-15 Sederma Cosmetic or Dermopharmaceutical Composition Comprising an Euglena Extract
US20070065392A1 (en) * 2005-07-12 2007-03-22 L'oreal Cosmetic composition with an amphiphilic lipid phase
US20100190740A1 (en) * 2008-12-18 2010-07-29 L'oreal Oil-in-water emulsion
US20130324499A1 (en) * 2011-02-05 2013-12-05 Croda International Plc Moisturiser blend
US20120225143A1 (en) * 2011-03-03 2012-09-06 Ranir, Llc Cold sore formulation and related method of manufacture
US20130164229A1 (en) * 2011-12-22 2013-06-27 Mary Kay Inc. Lip formulation
WO2015113307A1 (fr) * 2014-01-30 2015-08-06 Dow Corning Corporation Compositions pour application sur la peau pour réduire l'adhésion de particules de pollution sur la peau et leurs procédés de préparation
US20150272861A1 (en) * 2014-03-28 2015-10-01 Nusil Technology Llc Dispersions containing encapsulated materials and compositions using same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2678188C1 (ru) * 2018-08-31 2019-01-24 Общество с ограниченной ответственностью "Криопротект" Средство защиты кожи от холодового повреждения
WO2022129161A1 (fr) * 2020-12-16 2022-06-23 L'oreal Composition, en particulier composition cosmétique, à effet de flou

Similar Documents

Publication Publication Date Title
US20160081895A1 (en) Novel formulations
US11324686B2 (en) Occlusive formulations
US20210251869A1 (en) Skin treatment methods
US11253441B2 (en) Occlusive compositions
US11357712B2 (en) Method of use and compositions
WO2017074895A1 (fr) Nouvelles formulations
WO2017074893A1 (fr) Nouvelles formulations
US11510856B2 (en) Pramoxine compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16860591

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16860591

Country of ref document: EP

Kind code of ref document: A1